Our mission is simple—help patients across the globe who suffer from pain and chronic conditions. We are doing this by harnessing the power of nVNS, innovation, and technology to develop a safe and clinically backed treatment. Bringing new treatments to market will help improve patients' treatment options and lives.
BASKING RIDGE, N.J. , June 28, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq:ECOR), a commercial-stage bioelectronic medicine company, announced today it will present six abstracts across three primary headache disorders at the 60 th Annual Meeting of the American Headache Society (AHS) ( June
BASKING RIDGE, N.J. , June 28, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq:ECOR) today announced that the underwriters of its previously announced initial public offering of common stock have exercised in full their option to purchase an additional 780,000 shares of common
BASKING RIDGE, N.J., June 26, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq: ECOR ) today announced the closing of its initial public offering of 5,200,000 shares of common stock at a public offering price of $15.00 per share. The proceeds from this offering, net of
BASKING RIDGE, N.J. , June 21, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) today announced the pricing of its initial public offering of 5,200,000 shares of common stock at a public offering price of $15.00 per share. All of the shares of common stock are being offered by
gammaCore® Receives FDA Clearance for the Acute Treatment of Pain Associated with Migraine Headache in Adult Patients Basking Ridge, NJ, January 29, 2018 – electroCore, LLC (electroCore), a commercial-stage bioelectronic medicine company, announced today that it has received 510(k) clearance from
Investment to fund commercialization of gammaCore ® and further clinical development of nVNS Basking Ridge, NJ, November 29, 2017 – electroCore, a U.S.-based bioelectronic medicine healthcare company advancing better patient therapies through superior approaches to neuromodulation, announced
PRESTO demonstrates clinical benefit of gammaCore in the acute treatment of migraine compared to sham Basking Ridge, NJ, September 11, 2017 – electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological advancement, announced the first results
Nick Colucci Brings Invaluable Healthcare Communications Expertise to Enhance electroCore’s Continued Growth Basking Ridge, NJ, August 29, 2017 – electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological advancement, today announced that
electroCore launches gammaCore Patient Registry (GPR) to provide access to hand-held, easy-to-use device for the acute treatment of pain associated with episodic cluster headache in adults Basking Ridge, NJ, July 18, 2017 – electroCore, a neuroscience and technology company dedicated to
Francis R. Amato to Take on Additional Role to Help Further Position the Company for Growth Basking Ridge, NJ, June 21, 2017 – electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological advancement, today announced that Chief Executive
